6,828
Followers
24
Following
70
Posts
N/A
Reels
10
Highlights
9/3
Photos/Videos in last 12
Bio
A billion dollar breakthrough engine for health, at global scale. 13 programs. Working across 30 countries. More breakthroughs. Faster.
-
Avg likes
-
Avg comments
-
Engagement
0.2/wk
Posting
Likes and comments are still being collected for this account. Check back shortly.
Recent posts
Backstage at the 2025 #PowerWomensSummit, @melindafrenchgates, philanthropist and @pivotal_ventures founder, shared the news of a $100 million partnership between Pivotal Ventures and @wellcomeleap, the breakthrough health organization led by Regina Dugan. Read more at the link in our bio.
12 Sep 2025
Women represent 4 out of 5 autoimmune disease patients. More than 400 million women globally. These conditions cost women 4 to 9 healthy, productive years – the equivalent of losing 1 or more days a week to pain, fatigue, and joint swelling.
Despite this disproportionate burden, research has neglected study of the underlying biological causes and no existing therapy addresses a woman’s unique risk.
Risk for autoimmune disease rises and falls with a woman’s hormone transitions – surging at puberty, after childbirth, before and after menopause.
- Rheumatoid arthritis (RA): A woman’s risk of developing RA nearly triples when menopause comes early.
- Multiple sclerosis (MS): More than 1 in 4 women with MS experience a relapse in the 3 months after childbirth.
- Lupus: Flares triple in the year before a woman’s final menstrual period.
The timing isn’t a coincidence. The timing is the signal. Yet measurements of immune-endocrine interactions at these transitions are largely missing in research and clinical care.
Wellcome Leap’s new $50M program, AMPt: Autoimmune in Menopause and Pregnancy Transitions, jointly funded by @pivotaldotcom, is designed to change that.
AMPt aims to predict flares and disease onset with sufficient time and accuracy to intervene – moving from treating disease after the damage is done to anticipating it before it strikes.
The goal is to return the equivalent of one healthy day a week to those living with rheumatoid arthritis, multiple sclerosis, or lupus. At scale, that’s 52 more healthy days a year and 5 years across a lifetime for millions of women globally.
1 day a week. It’s time for her to take it back.
Learn more: https://wellcomeleap.org/programs/ampt
02 Nov 2026
4 out of 5 people living with autoimmune disease are women. Not by chance. Not simply because women live longer.
Why are women so disproportionately affected? And what would it take to change that?
It’s time we find out.
Coming soon: A new $50M Wellcome Leap research program, jointly funded with @pivotaldotcom, focused on autoimmune disease in women.
30 Oct 2026
Each year, nearly two million babies are stillborn around the world. Behind every number is a family experiencing an unimaginable loss. As part of our commitment to save the lives of more moms and babies, we're aiming to reduce stillbirths to less than 1 million per year—that's more than half—by 2045.
In collaboration with @wellcomeleap, we’re investing $100 million to develop a new program called Uzima, advancing promising new tools that could help ensure more mothers get to bring their babies home.
Learn more about the work and why we’re calling on others to join us at the link in our bio.
27 Oct 2026
Stillbirth is the fifth leading cause of death worldwide. More deaths each year than HIV, malaria, and direct heat-related deaths combined.
Yet many of the tools used throughout pregnancy and childbirth have remained largely unchanged for decades: A blood pressure cuff. A tape measure. A dipstick.
What if we could detect life-threatening complications in utero before it's too late?
This week, Wellcome Leap and the @gatesfoundation announced Uzima: A Stillbirth Prevention Program, a $100 million joint commitment to demonstrate that stillbirth rates can be reduced by half across select countries over the next decade.
Building on promising innovations already developed, Uzima aims to identify risks earlier, detect complications sooner, and demonstrate how integrated approaches to care can prevent more stillbirths.
Success and global scaling within our lifetime would mean as many as one million more babies going home safely with their families. Every year.
On Pregnancy and Infant Loss Remembrance Day, we remember the babies lost and the families whose lives have been forever changed. Their stories are a powerful reminder of why this work matters – and what is at stake.
https://wellcomeleap.org/news/uzima_partnership/
15 Oct 2026
The @gatesfoundation and @wellcomeleap have committed $100 million to stillbirth prevention.
With nearly 2 million stillbirths occuring annually, the two organizations have formed Uzima: A Stillbirth Prevention Program to cut cases in half over the next decade, starting in countries most affected.
The program will partner with healthcare systems to validate clinical protocols and expand education for providers and families to establish a global standard of care. To kickstart the initiative, Uzima will focus on sub-Saharan Africa, where nearly half of global stillbirths occur.
Uzima will evaluate technologies and interventions that could reduce stillbirth risks and improve maternal-fetal health, including biomarker- and imaging-based diagnostics, AI-enabled ultrasounds and advanced screenings, in-labor monitors, decision-support tools, and personalized support and navigation systems.
📩 Subscribe to Femtech Insider for the latest women’s health headlines — delivered weekly → link in bio.
14 Oct 2026
What if one million more babies could go home safely with their families every year?
Today, Wellcome Leap and @gatesfoundation announced Uzima: A Stillbirth Prevention Program – a $100 million joint commitment with the ambition of demonstrating that stillbirth rates can be cut in half.
Leaders from both organizations discussed the new partnership today at the @worldhealthsummit in Berlin.
Every 17 seconds, a baby is born still. Nearly 2 million babies every year. The tools we have for mothers and babies, our systems of care for pregnancy and childbirth, have changed little in decades.
We can do better. We must do better.
Through Wellcome Leap's In Utero program and the Gates Foundation’s Maternal, Newborn, Child Nutrition and Health (MNCNH) program, promising new technologies have emerged to identify risks earlier, detect complications sooner, and help health workers intervene in time.
Uzima will build on these advances, evaluating how different tools can work together to reduce stillbirth rates by 50% across select countries over the next decade – and establish a model that can ultimately be scaled around the world.
Both organizations have committed $50 million over the first three years. But achieving the full ambition will take more of us – from governments and philanthropies to investors and innovators.
The goal is clear: More mothers and babies going home safely.
Read the announcement and learn how to get involved: https://wellcomeleap.org/news/uzima_partnership/
Explore Leap’s broader women’s health portfolio and follow us for updates: https://wellcomeleap.org/womens-health/
12 Oct 2026
Today, we’re announcing the global team of 17 selected performers for Resistance Networks – Wellcome Leap’s $50 million program, with support from Bayer, focused on reducing the threat of antimicrobial resistance (AMR).
Antibiotics are one of the foundations of modern medicine. But we’re losing their power as antibiotic resistance continues to spread.
In 2021 alone, 1.14 million deaths were directly attributable to antibiotic resistance – and without intervention, that number is projected to exceed 1.91 million annually by 2050.
We need new antibiotics, but developing them is slow and costly. And while public health and stewardship efforts are essential, they can’t address the challenge alone.
The Wellcome Leap Resistance Networks program aims to use epidemiological methods to detect, model, design, and test interventions that could prevent or slow the development of resistance in bacterial networks.
Direct analyses of the genome dynamics in different communities will identify risk points for interventions that can stop the emergence and spread of antibiotic resistance.
And it matters. Because slowing the spread of resistance could avert more than 1,300 deaths a day from resistant E. coli and Klebsiella by 2050 – and help to protect the next generation of antibiotics from emerging resistance.
Meet the researchers taking on this challenge:
🔗 https://wellcomeleap.org/programs/resistance-networks/
03 Oct 2026
“I have seen extraordinary teams make a difference in national security, technology, and health. I have watched ideas become innovations that changed the way people live. But I believe the work Wellcome Leap is doing to close the gap in women’s health research is among the most important of my life. It is a chance to correct a historic wrong, to close a gap that should never have existed, and to honor the dignity of half the world’s population by giving us the science, the medicine, and the care we deserve.
Reaching the scale of impact women deserve will take more of us. It will take a coalition of leaders across philanthropy, government, and the private sector, willing to commit at the level the problem demands. At Leap, we have the model, the network, the commitment, and the capacity to put new resources to work on a global scale within 100 days. And the range of problems we could potentially solve is vast.
Many have raised awareness. Now we must raise expectations. So join us. Because the question is not whether we can make the next decade one of extraordinary progress in women’s health. The question is whether we will.”
– Regina E. Dugan, CEO, Wellcome Leap
🔺Read and share Regina’s call to action: https://www.devex.com/news/sponsored/opinion-it-s-time-women-have-waited-long-enough-111019
🔺Help raise expectations for women’s health—share the facts: https://wellcomeleap.org/womens-health-research-fact-sheet/
🔺Follow us for updates
#WomensHealth #WomensHealthResearch
29 Sep 2026
We are now accepting proposals for Resistance Networks, Wellcome Leap’s $50 million program, with support from Bayer, focused on reducing the threat of antimicrobial resistance (AMR).
AMR is a leading and growing cause of mortality worldwide. In 2021, over 1 million deaths were directly attributable to antibiotic resistance. The development of new antibiotics is necessary, but it is slow and expensive. Public health and stewardship strategies are helping, but they can’t keep up.
What if we could use epidemiological methods to detect, model, design, and test interventions that prevent or slow the movement and exchange of resistance in bacterial networks?
The goal of Resistance Networks is to identify when and where plasmid carrying antibiotic resistance genes have epidemic-like potential to spread within and between human bacterial networks.
If revealed, new epidemiological model-based interventions could slow the spread of resistance to current antibiotics – averting more than 1,300 deaths a day from resistant E. coli and Klebsiella by 2050. And secure the next generation of antibiotics against the emergence of resistance.
Proposals due: 4 September 2026 at 11:59pm ET
Learn more: https://wellcomeleap.org/programs/resistance-networks/
28 Aug 2026
What happens when a gaming company takes on the global shortage of surgeons – and rethinks how surgical training is designed, delivered, and scaled?
An estimated 143 million operations are needed each year to meet basic health needs globally, with the greatest gaps in low-income settings.
Traditional laparoscopic simulators can cost up to $200K per unit, putting high-quality surgical training out of reach for many institutions around the world.
In Wellcome Leap’s SAVE program, Grendel Medical set out to build a different solution. Laptitude is an AI-powered, portable laparoscopic training platform designed to expand access to surgical training.
Designed for scale:
◾ 100x+ lower hardware cost: Replacing 6-figure laparoscopic simulators with an accessible platform requiring just $593 in hardware, plus a $36/month subscription.
◾ Unlimited practice scenarios: AI generates infinite and diverse anatomy and pathology variations, allowing surgery residents to train on rare complications before entering the operating room. Think flight simulator for surgery.
◾ From concept to global reach in 3 years: Launched commercially in January 2026 and already sold across 45 countries, demonstrating how unconventional teams and accelerated execution can move new technologies into practice faster.
◾Global validation: Active validation studies are underway in 4 countries – the Netherlands, India, Kenya, and Guatemala – with one paper already published, proving its efficacy across diverse healthcare settings.
What makes Laptitude different isn’t just the technology, it's the team behind it. Drawing on more than 20 years of experience in developing games for training, Grendel Medical brought together programmers, artists, game designers, AI experts, and clinicians to approach surgical simulation as a software design challenge, rather than simply a hardware one.
High-quality surgical training can improve access to safe surgery around the world. These are the kinds of breakthroughs we need. More of them. And faster.
See the technology in action.
Learn more at laptitude.com
#GlobalHealth #Surgery #HealthEquity
12 Aug 2026
Antibiotics are one of the foundations of modern medicine.
But we’re losing their power – currently, 1 in 6 bacterial infections are resistant to standard first-line treatments. In 2021 alone, resistant infections were linked to 1.14 million deaths worldwide. Without new approaches, resistant bacterial infections are projected to kill more than 8 million people annually by 2050.
Today, we’re announcing the selected performers for Focused Antibiotics – Wellcome Leap’s $50M program to transform how antibiotics are delivered.
Approximately 85-90% of human bacterial infections are local, affecting areas such as the bladder, middle ear, skin, or respiratory tract. However, nearly all antibiotics are administered systemically – through oral tablets or intravenous injections – exposing the entire body to treatment and turning the gut into a “resistance factory.”
Focused Antibiotics brings together researchers from across disciplines to pursue a different approach: reformulating antibiotics so they reach the site of infection while sparing the gut microbiome – all without compromising treatment efficacy.
If successful, scaling these new formulations for the most common outpatient bacterial infections could reduce the global annual occurrence of antibiotic-driven resistant infections by as much as 40%, potentially avoiding more than 100 million resistant infections within a decade of use.
Meet the teams working to make this possible:
🔗 www.wellcomeleap.org/focused-antibiotics
29 Jul 2026
Follower tracking
We have started recording @wellcomeleap, but only 1 observation so far — not enough to show a trend yet. Track it daily →
Download @wellcomeleap's data
Everything below is derived from this account, priced on the counts shown. Delivered as CSV by emailed link.
You only pay for rows we deliver. Counts are the maximum available today; if an export comes back smaller, the difference is refunded automatically. Counts as last collected 1 day, 12 hours ago.
Tracking
A monthly plan, not a download: we keep reading @wellcomeleap and email you what changed.
Other reports
Not downloads of this account: they take their own inputs.
Similar accounts
Accounts we track that share hashtags, mentions or bio topics with @wellcomeleap.
@rachelzegler
2.6M followers
Also mentions @gatesfoundation
@actionagainsthunger
32.6K followers
Also uses #globalhealth
@elmaphilanthropies
1,604 followers
Also uses #globalhealth
@globalpolioeradication
2,882 followers
Also mentions @gatesfoundation
@curlylyric22
309.7K followers
Also uses #surgery
@swhr_official
4,105 followers
Also uses #womenshealthresearch
@opspaho
521.0K followers
Also mentions @gatesfoundation
@forbeswomen
482.0K followers
Also uses #powerwomenssummit